Abstract： Objective To explore the current research status,trends and hotspots of blinatumomab in the treatment of acute lymphoblastic leukemia in the past 10 years.Methods The related literature on blinatumomab in the treatment of acute lymphoblastic leukemia was retrieved from the CNKI database and Web of Science Core Collection database from 2014 to 2023.The literature was visualized and analyzed using CiteSpace 6.1.R6 software.Results The CNKI database in-cluded a total of 8 Chinese articles,showing an increasing trend in publication volume year by year.However,due to insuffi-cient literature inclusion,visual analysis could not be performed.The Web of Science Core Collection database included a total of 784 English articles from 62 countries and 331 institutions.Jabbour Elias was the author who has published the most articles in this field,with a total of 37,and the Anderson Cancer Center in the United States was the institution that published the most,with a total of 97.The United States contributed the most articles(454)among the countries.The top frequent keyword was minimal residual disease,and the keyword surge indicates that children still have a sudden emer-gence.Among the top ten most cited articles,four reported on the efficacy of blinatumomab in the treatment of acute lym-phoblastic leukemia.The cited literature formed eight major themes through keyword clustering,and currently the most ac-tive clustering is children and tyrosine kinase inhibitors.Conclusion In the past 10 years,the research on blinatumomab in the treatment of acute lymphoblastic leukemia has mainly focused on its effectiveness and safety in pediatric populations.Current research hotspots continue to center around pediatric populations,with future trends pointing towards combination therapies involving blinatumomab alongside inotuzumab ozogamicin or tyrosine kinase inhibitors.